Physician profile
Alwin Joy
NPI 1538856851
$715.05
in general payments reported to CMS, 2019-2025
15 companies · $79.74 in 2025
The $79.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $485 · 2024: $150 · 2025: $79.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.05 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $149.83 | 2024 | Activ.A.C. |
| Astellas Pharma US INC | $118.72 | 2023 | Padcev |
| Morphosys, US INC. | $84.63 | 2023 | Monjuvi |
| Smith+Nephew, INC. | $79.74 | 2025 | Collagenase Santyl |
| Abbvie INC. | $49.75 | 2023 | |
| Daiichi Sankyo INC. | $40.35 | 2023 | Enhertu |
| Eisai INC. | $39.56 | 2023 | |
| Alexion Pharmaceuticals, INC. | $34.17 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $21.79 | 2023 | |
| Incyte Corporation | $19.45 | 2023 | Jakafi |
| Karyopharm Therapeutics INC. | $18.91 | 2023 | Xpovio |
| Sobi, INC | $15.86 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.16 | 2023 | |
| Stemline Therapeutics INC. | $14.07 | 2023 | Orserdu |
| Janssen Biotech, INC. | $14.06 | 2023 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alwin Joy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.